ApoA-1 versus HDL-C as markers of cardiovascular risk
Journal of Clinical Lipidology · 2026-05 · 20 (5) · 1040-1047
DOI: 10.1016/j.jacl.2026.02.017 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Clinical Lipidology, 2026-05. Verfasst von Selin Bilgic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, 1001 Decarie Blvd, Montrea…. Hauptthemen laut MEDLINE: Apolipoprotein A-I, Cholesterol, HDL, Atherosclerosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Conflicting results have been reported as to the relative importance of apoA-1 versus HDL-C as markers of ASCVD risk.
Methods
Residual discordance analysis with Cox proportional hazard models comparing apoA-1 and HDL-C as markers of ASCVD risk was applied to a sample of 291,995 UK Biobank, followed for a median of 11 years. Interaction test for the two markers and estimation of the effects of partitioning HDL-C into apoA-I, log-triglyceride and the remaining residual were also performed.
Results
ApoA-1 and HDL-C had similar associations with ASCVD risk (HRs of 0.85, p-value < 0.001 for both). The residual of HDL-C added significantly to the risk associated with apoA-1 as did the residual of apoA-1 to HDL-C. There was a statistically significant interaction between apoA-I and HDL-C ( HR = 1.05, 95% CI: (1.04, 1.06); p < 0.001 ). Decomposing HDL-C into the 3 components, apoA-I accounted for the largest portion of the effect with a HR of 0.85 95%CI: (0.83, 0.86) with smaller effects for lnTG: 1.04 (1.02, 1.06) and residual of HDL-C: 0.98 95%CI: (0.96, 0.995).
Conclusions
HDL-C and apoA-1 have associations of equivalent strength with ASCVD risk with significant interaction modifying the effect of one by the other. Upon decomposition, ApoA-I retained more of the effect of HDL-C as compared to log-triglycerides. While only observational, the results are consistent with the relation of HDL to risk not being determined by the concurrent level of triglyceride. Clinical Perspective The plasma levels of HDL-C and apoA-I are potent predictors of cardiovascular risk. However, there are few data comparing the relative precision of HDL-C and apoA-I for this purpose. Moreover, the risk of low HDL-C has been attributed to concurrent hypertriglyceridemia, consequently downgrading the potential importance of HDL in predicting or explaining risk. Novel Findings Based on residual discordance analysis, HDL-C and apoA-I have similar predictive precision for ASCVD risk. However, each adds significantly to the other and. Moreover, triglycerides account for only a small portion of the risk attributable to HDL with apoA-I accounting for the principal portion. Clinical Significance HDL, whether measured as HDL-C or apoA-I, is a potent predictor of ASCVD risk. It remains essential to search for the biological basis or bases for these relationships.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, 1001 Decarie Blvd, Montreal, Quebec H4A 3J1, Canada (Bilgic, K. Pencina, M. Pencina, Dufresne, T…
Zitieren
APA
Bilgic, S., Pencina, K., Pencina, M., Dufresne, L., Thanassoulis, G., & Sniderman, A. (2026). ApoA-1 versus HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology, 20(5), 1040-1047. https://doi.org/10.1016/j.jacl.2026.02.017
Vancouver
Bilgic S, Pencina K, Pencina M, Dufresne L, Thanassoulis G, Sniderman A. ApoA-1 versus HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology. 2026;20(5):1040-1047. doi:10.1016/j.jacl.2026.02.017
BibTeX
@article{Bilgic2026,
author = {Bilgic, Selin and Pencina, Karol and Pencina, Michael and Dufresne, Line and Thanassoulis, George and Sniderman, Allan},
title = {ApoA-1 versus HDL-C as markers of cardiovascular risk},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {5},
pages = {1040--1047},
doi = {10.1016/j.jacl.2026.02.017}
}
EUVIMED